Tvardi Therapeutics (LTS:0HTC) Construction In Progress : £0.00 Mil (As of Mar. 2025)

View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Construction In Progress?

Tvardi Therapeutics Construction In Progress Historical Data

The historical data trend for Tvardi Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Construction In Progress Chart

Tvardi Therapeutics Annual Data

Trend

Dec22

Dec23

Construction In Progress

Tvardi Therapeutics Quarterly Data
	Dec22	Dec23	Mar24	Sep24	Mar25
Construction In Progress	-	-	-	-	-

Tvardi Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Tvardi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

TVRD:USA 69C:Germany

Address

3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478

Website

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines